After two years of follow-ups, the addition of Genmab's Darzalex to standard treatments of multiple myeloma still ensures certain patients a progression free survival. In fact, the combination is more effective than the standard therapy alone.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.